Rezpegaldesleukin clinical trials
Rezpegaldesleukin is named as an intervention in 4 current clinical trials in our USA, Canada, Germany, Spain, Poland, Czechia and Australia registers. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Nektar Therapeutics (3). The most-studied condition is Moderate-to-Severe Atopic Dermatitis. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
How Rezpegaldesleukin works
All drug targets →- Alopecia areataPhase 2
- Atopic eczemaPhase 2
- Systemic lupus erythematosusPhase 2
- Type 1 diabetes mellitusPhase 2
- Ulcerative colitisPhase 2
- PsoriasisPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095458, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Rezpegaldesleukin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Rezpegaldesleukin
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371 · Moderate-to-Severe Atopic Dermatitis
|
Phase 3 | Recruiting | Nektar Therapeutics | USA |
|
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07711418 · Moderate-to-Severe Atopic Dermatitis
|
Phase 3 | Recruiting | Nektar Therapeutics | USA |
|
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
NCT07142252 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus
|
Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Canada |
|
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741 · Moderate to Severe Atopic Dermatitis
|
Phase 2 | Active, closed | Nektar Therapeutics | USA, Germany, Spain, Poland, Czechia, Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Rezpegaldesleukin in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Rezpegaldesleukin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age with Moderate-to-Severe Atopic Dermatitis (ZENITH AD-1)
2025-524925-42-00 · CTIS ↗ · Skin and Connective Tissue Diseases
|
Phase 3 | Authorised | Nektar Therapeutics | Lithuania, Slovakia, Bulgaria + 6 more |
|
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age with Moderate-to-Severe Atopic Dermatitis
2025-525129-11-00 · CTIS ↗ · Immune System Diseases
|
Phase 3 | Authorised | Nektar Therapeutics | Portugal, Austria, Poland + 6 more |
Conditions studied with Rezpegaldesleukin
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Nektar Therapeutics | 3 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Rezpegaldesleukin trials
How many clinical trials are testing Rezpegaldesleukin?
4 current trials in our USA, Canada, Germany, Spain, Poland, Czechia and Australia registers name Rezpegaldesleukin (also registered as NKTR-358) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Rezpegaldesleukin trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 2 with sites in USA and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rezpegaldesleukin clinical trials?
Nektar Therapeutics (3) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rezpegaldesleukin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rezpegaldesleukin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rezpegaldesleukin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.